Nanalysis Sci Stock Price, News & Analysis

Nanalysis Scientific Corp. reported its Q2 2022 results, highlighting a 19% revenue growth year-over-year to $5.187 million, despite a net loss of $2.532 million compared to a net income of $222,000 in Q2 2021. The gross margin decreased from 67% to 62%. The company secured a $160 million service contract with CATSA effective May 25, 2022. Due to operational challenges in scaling its NMR sales, the company is restructuring its sales model and focusing on increasing production capabilities. Nanalysis anticipates revenue growth will improve in the current quarter.

Nanalysis Scientific Corp. will hold a conference call on August 25, 2022, at 5:00 PM ET to discuss its second-quarter financial results for the period ending June 30, 2022. CEO Sean Krakiwsky and Interim CFO Randall McRae will lead the discussion. Investors can participate by phone or through a live webcast. A follow-up Q&A session for European investors is scheduled for August 26 at 8:30 AM ET. Nanalysis specializes in portable NMR technology for various industries and recently expanded its product offerings with advanced devices.

Nanalysis Scientific Corp. announced a management transition on July 21, 2022, with CFO Luke Caplette stepping down but remaining as a part-time consultant. Corporate Controller Randall McRae has been appointed as interim CFO. The company appreciates Caplette's contributions and expresses confidence in McRae’s experience and leadership during this transition. McRae brings over 15 years of experience, having worked with MNP LLP/Deloitte LLP and co-founded a cloud accounting firm. Nanalysis focuses on developing portable Nuclear Magnetic Resonance spectrometers for various industries.

Nanalysis Scientific Corp. will participate in two upcoming investment conferences. The first is the LD Micro Conference on June 7, 2022, at 4:30 PM ET, where investors can engage in 1x1 meetings. The second event is the OTCQX Best 50 Virtual Investor Conference on June 16, 2022, at 1:00 PM ET, also featuring virtual 1x1 sessions. Nanalysis specializes in portable NMR technology and aims to enhance investor engagement through these interactive presentations.

Nanalysis Scientific Corp. reported its first-quarter results for 2022, highlighting a consolidated revenue of $5,554K, a 69% increase year-over-year. However, the company faced a net loss of $1,492K, compared to a loss of $467K in the same period last year. The gross margin declined to 60% from 64%. Significant developments included a $160 million multi-year service contract with CATSA and a $4,985,000 funding commitment from the Canadian government.

Nanalysis Scientific Corp. announced a six-year contract valued at $160 million with the Canadian Air Transportation Security Authority (CATSA) to provide service and maintenance for security screening equipment. This contract, effective from May 25, 2022, may be renewed for an additional five years, creating a potential eleven-year recurring revenue opportunity. The project’s phase-in process is underway, targeting completion by the end of Q1 2023. This win is expected to enhance Nanalysis's footprint in the security vertical and contribute to shareholder value.

Nanalysis Scientific Corp. will host a conference call on May 31, 2022, at 5:00 PM ET to discuss the quarterly results ending March 31. The call is accessible via phone and a listen-only webcast. The Annual General Meeting (AGM) is set for June 22, 2022, at 11:00 AM ET, with shareholders encouraged to vote by proxy due to health concerns. Nanalysis, trading as OTCQX: NSCIF, specializes in portable NMR and MRI technologies.

Nanalysis Scientific Corp. (OTCQX:NSCIF) will present at the Planet MicroCap Showcase 2022 on May 4, 2022, at 5:30 PM PT in Las Vegas. CEO Sean Krakiwsky will lead the presentation and engage in one-on-one investor meetings. The event will be accessible via a live webcast. Nanalysis is recognized for its innovative portable NMR technology, serving industries such as pharma, biotech, and oil & gas. The company continues to enhance its product offerings, including a new 100MHz NMR device, reinforcing its position in the market.

Nanalysis Scientific Corp. announced its financial results for Q4 and full year of 2021, showcasing a remarkable 104% revenue growth to $16,043K. The company improved its net loss to $1,772K from a previous loss, while gross margins slightly decreased from 66% to 64%. Strategic highlights included a $4.98 million funding commitment from the Canadian government and acquisitions of K’Prime Technologies and Quad Systems. The firm is optimistic about future growth, supported by a healthy balance sheet and strong product demand.